Status:
TERMINATED
Half-Dose Intracoronary Abciximab Bolus Improves the Mortality Outcome Compared to Standard Intravenous Regimen
Lead Sponsor:
Azienda Sanitaria Ospedaliera
Collaborating Sponsors:
Cardiologia 2 - Emodinamica - Ospedale Maggiore, Novara, Italy
Conditions:
Coronary Disease
Myocardial Infarction
Eligibility:
All Genders
50+ years
Phase:
PHASE4
Brief Summary
The aim of our study was to demonstrate that, during a percutaneous coronary intervention, even smaller amounts of abciximab than standard dose, injected locally, could achieve a rapid thrombus resolu...
Detailed Description
Patients both with acute myocardial infarction and unstable angina are prone to extensive intracoronary thrombosis, leading to acute deterioration during percutaneous coronary intervention or thrombos...
Eligibility Criteria
Inclusion
- presenting with unstable angina
- presenting with acute myocardial infarction
- eligibility for percutaneous coronary intervention
Exclusion
- presenting with cardiogenic shock
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
End Date :
July 1 2005
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT00320229
Start Date
December 1 2004
End Date
July 1 2005
Last Update
May 16 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cardiologia 2 - Emodinamica - Ospedale Maggiore
Novara, Italy, 28100